Oral minoxidil for hair loss: efficacy, dosage and risks

This might seem odd, given that the molecule was originally developed to treat severe hypertension, not baldness. And yet. The clinical data is hard to dismiss: a recent meta-analysis of 2,933 patients shows significant improvement in nearly half of all cases, and a multicentre study of 1,404 patients found a discontinuation rate due to adverse effects of just 1.7%. Those are strong numbers.

One thing to be clear about: oral minoxidil is not approved for treating hair loss. Its use for this purpose is off-label, outside the indications validated by health agencies. Is this a passing trend or a real step forward in managing androgenetic alopecia? Here’s what the evidence actually says.

From blood pressure drug to hair treatment: an accidental discovery

The backstory is worth knowing. When Upjohn Laboratories developed minoxidil in the 1960s, the goal was straightforward: lower blood pressure in hypertensive patients who hadn’t responded to other drugs. Doctors quickly noticed an unexpected side effect. Patients were growing hair, and not just on their heads. Some saw new growth on their backs and arms. Unwelcome if you’re a cardiologist, but very interesting if you’re a dermatologist.

That accidental observation led to the development of topical minoxidil in lotion and foam form, which became a mainstay of hair loss treatment.

Why so many patients give up on the lotion

The problem with the topical form is the discipline it demands. You need to apply it once or twice a day, every day, without exception. It irritates the scalp in some people, causes flaking, and leaves hair greasy or sticky. After a few months, plenty of patients simply stop using it. Sticking with it long term is genuinely difficult.

Against this backdrop, dermatologists (initially in Australia and Spain) started prescribing oral minoxidil at much lower doses than those used in cardiology. One tablet a day, no sticky residue, no local irritation. For many patients, that’s reason enough to stay on treatment.

How oral minoxidil works on your follicles

The mechanism isn’t fully understood, but we know quite a lot. Minoxidil stimulates ATP-dependent potassium channels in the cells of the dermal papilla, the “base” of the hair follicle. Blood vessels in the scalp dilate, delivering more oxygen and nutrients. But that’s only part of it.

The molecule also activates the Wnt/β-catenin signalling pathway, which is central to follicular regeneration, and boosts the release of the growth factor VEGF. It may even reduce the expression of type II 5α-reductase, the enzyme that converts testosterone into DHT, the hormone responsible for progressively miniaturising follicles in pattern baldness.

Shedding: alarming but normal

In practical terms, minoxidil pushes resting (telogen) follicles into the growth (anagen) phase and prolongs that active phase. This explains the well-known shedding at the start of treatment: old, weakening hairs fall out to make way for stronger new ones. It can be alarming if nobody warns you about it, but it means the drug is doing its job.

Why the oral route works for non-responders

When swallowed, minoxidil passes through the liver, which converts it into minoxidil sulphate, its active form. Some patients’ follicles have low sulfotransferase activity, which is why the lotion didn’t work well for them. The tablet sidesteps this problem: the medication arrives at the scalp already activated, without relying on local enzyme activity. For these patients, switching to the oral form often makes a real difference.

What the clinical evidence shows

The data has grown considerably. A systematic review covering 17 studies and 634 patients reports that 61 to 100% of patients with androgenetic alopecia experience objective clinical improvement on oral minoxidil. The range is wide, but the direction is consistent.

A Brazilian randomised trial directly compared oral minoxidil (5 mg/day) to the 5% topical form in 90 men over 24 weeks. Results were comparable on the frontal area, but the oral form proved superior on the vertex. Most likely because the medication circulates in the bloodstream and distributes evenly, without the inconsistencies of topical application.

What dosages are used in practice?

Efficacy is dose-dependent. Each additional milligram per day corresponds to an average increase of 47.1 hairs/cm² and a 1.4 μm increase in hair diameter after six months.

For women, dermatologists typically prescribe between 0.25 and 1.25 mg per day. For men, between 2.5 and 5 mg per day, with a gradual increase. These doses are well below the 10 to 40 mg used in cardiology, which explains the favourable safety profile.

Be realistic about what to expect: oral minoxidil stabilises hair loss and improves density. It won’t regrow a full head of hair where follicles have been dormant for years. Areas that have been completely bald for a long time won’t respond, regardless of dosage. Better to know this upfront.

Side effects: what you need to know before starting

The most common side effect is hypertrichosis: hair growth on other parts of the body, particularly the face, arms, and back. The multicentre study of 1,404 patients reported a rate of 15.1%, though only 0.5% of patients stopped treatment because of it. Women are more affected, and the severity depends on dosage. At 0.25 mg per day, the risk is minimal. At 5 mg, it becomes more frequent, which is why women are usually started on lower doses.

Cardiovascular effects and contraindications

At the low doses used for hair loss, cardiovascular effects are uncommon: dizziness in 1.7% of patients, fluid retention in 1.3%, tachycardia in 0.9%. Periorbital oedema (slight swelling around the eyes) affects only 0.3%. Serious complications are rare.

A baseline cardiac assessment is recommended before starting, with blood pressure and heart rate monitoring during the first few months. Oral minoxidil is contraindicated in heart failure and pregnancy, and women of childbearing age must use reliable contraception throughout treatment.

Oral minoxidil in the UK: where do we stand?

In the UK, oral minoxidil does not have a marketing authorisation for hair loss. Only the topical form (2% and 5%, sold over the counter as Regaine) is licensed for this indication. That doesn’t prevent dermatologists from prescribing it off-label, under their own clinical responsibility, provided they inform the patient.

An expert consensus published in 2023 set out recommendations to guide this practice. The situation may well change. Favourable data continues to accumulate in peer-reviewed journals, and the question of updating the official indications is being discussed more seriously. For now, this remains a specialist prescription. Buying oral minoxidil online and self-medicating without a proper assessment or follow-up is an unnecessary risk.

When minoxidil is no longer enough

Oral minoxidil, alone or combined with finasteride, is a solid option for slowing hair loss and improving density. Low-level laser therapy can complement the approach. But none of these treatments will regenerate areas where follicles have permanently disappeared. For that, a hair transplant in Turkey is the next step, and the only option that restores density where medication can no longer help.

Dr Emrah Cinik has performed over 50,000 procedures across more than 20 years. His clinic offers treatment plans combining medication with Sapphire FUE and DHI surgery. PRP (Platelet-Rich Plasma) treatment is included in all packages, and Regenera Activa, a mesenchymal stem cell treatment, is available to support regrowth after the procedure.

Post-operative follow-up meets ISHRS standards, with a medication protocol tailored to each patient. If you’d like to explore your options, a free hair consultation is the place to start. You can also look at before-and-after results and follow the month-by-month progress of a transplant to get a realistic sense of what’s possible.

In practice, the best results come from combining medication with surgery when the hair loss warrants it.

Scientific references

Asilian, A., Farmani, A., & Saber, M. (2024). Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial. Journal of Cosmetic Dermatology, 23(3), 949-957. https://pubmed.ncbi.nlm.nih.gov/38031516/

Gupta, A. K., Hall, D. C., Talukder, M., & Bamimore, M. A. (2022). There is a positive dose-dependent association between low-dose oral minoxidil and its efficacy for androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology, 36(12), e957-e960. https://pmc.ncbi.nlm.nih.gov/articles/PMC9485924/

Jimenez-Cauhe, J., Saceda-Corralo, D., Rodrigues-Barata, R., et al. (2020). Safety of low-dose oral minoxidil treatment for hair loss: A systematic review and pooled-analysis of individual patient data. Dermatologic Therapy, 33(6), e14106. https://pubmed.ncbi.nlm.nih.gov/32757405/

Mysore, V., Parthasaradhi, A., Kharkar, R. D., et al. (2023). Low-dose oral minoxidil in the treatment of alopecia: Evidence and experience-based consensus statement of Indian experts. Indian Dermatology Online Journal, 14(6), 783-793. https://pmc.ncbi.nlm.nih.gov/articles/PMC10763725/

Ong, M. M., Li, Y., & Lipner, S. R. (2025). Oral minoxidil for alopecia treatment: Risks, benefits, and recommendations. American Journal of Clinical Dermatology. https://pubmed.ncbi.nlm.nih.gov/41118052/

Perera, E., & Sinclair, R. (2022). Role of oral minoxidil in patterned hair loss. Indian Journal of Dermatology, Venereology, and Leprology, 88(6), 729-733. https://pmc.ncbi.nlm.nih.gov/articles/PMC9650732/

Randolph, M., & Tosti, A. (2021). Oral minoxidil treatment for hair loss: A review of efficacy and safety. Journal of the American Academy of Dermatology, 84(3), 737-746. https://pubmed.ncbi.nlm.nih.gov/32622136/

Ramos, P. M., Miot, H. A., et al. (2024). Oral minoxidil vs topical minoxidil for male androgenetic alopecia: A randomized clinical trial. JAMA Dermatology, 160(6), 620-627. https://pubmed.ncbi.nlm.nih.gov/38598226/

Sinclair, R., Torkamani, N., & Jones, L. (2024). Low-dose oral minoxidil for alopecia: A comprehensive review. Journal of Clinical Medicine, 13(3), 648. https://pmc.ncbi.nlm.nih.gov/articles/PMC10806356/

Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., et al. (2021). Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology, 84(6), 1644-1651. https://pubmed.ncbi.nlm.nih.gov/33639244/

Wang, X., Li, Y., Zhang, R., et al. (2025). Efficacy and safety of oral minoxidil in the treatment of alopecia: A single-arm rate meta-analysis and systematic review. Frontiers in Pharmacology, 16, 1528133. https://pmc.ncbi.nlm.nih.gov/articles/PMC12188453/